J Rubió-Casadevall1,2,3, M Puig-Vives4,5, M Puigdemont4,6,7, L Vilardell4,5, A Carbó-Bagué8, R Marcos-Gragera4,9,5, N Vilar-Coromina4,9,10. 1. Medical Oncology Department, Hospital Josep Trueta, Catalan Institute of Oncology of Girona, Av. França s/n, 17005, Girona, Spain. jrubio@iconcologia.net. 2. Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain. jrubio@iconcologia.net. 3. School of Medicine, University of Girona (UdG), Girona, Spain. jrubio@iconcologia.net. 4. Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain. 5. Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan Department of Health Government of Catalonia, Catalan Institute of Oncology, Girona, Spain. 6. University Hospital Josep Trueta Cancer Registry Coordinator, Catalan Institute of Oncology of Girona, Girona, Spain. 7. School of Nursery, University of Girona (UdG), Girona, Spain. 8. Medical Oncology Department, Hospital Josep Trueta, Catalan Institute of Oncology of Girona, Av. França s/n, 17005, Girona, Spain. 9. School of Medicine, University of Girona (UdG), Girona, Spain. 10. Dermatology Department, University Hospital Josep Trueta, Catalan Institute of Health, Girona, Spain.
Abstract
INTRODUCTION: We conducted a population-based study on the Girona Cancer Registry (Spain) for the period 1994-2013 to determine patterns of change in the incidence of melanoma, which is increasing in many countries, and patient survival in our geographical area. MATERIALS AND METHODS: Using the standard registration rules for cancer registries, we calculated crude and standardized incidence rates as well as their trends. We also analysed the observed survival, 1-year conditioned survival and relative survival at 3, 5 and 10 years. RESULTS: Our crude incidence rate was 9.13 cases/100,000 inhabitants for invasive and 2.59 for "in situ" melanomas. A statistically significant increase in incidence was found for melanomas of less than 1 mm in Breslow index and in males. 10-year observed and relative survival rates were 64.1 and 83.1%, respectively. CONCLUSIONS: We found an increasing trend in the incidence of low-risk melanoma and a survival rate similar to that reported elsewhere in Europe.
INTRODUCTION: We conducted a population-based study on the Girona Cancer Registry (Spain) for the period 1994-2013 to determine patterns of change in the incidence of melanoma, which is increasing in many countries, and patient survival in our geographical area. MATERIALS AND METHODS: Using the standard registration rules for cancer registries, we calculated crude and standardized incidence rates as well as their trends. We also analysed the observed survival, 1-year conditioned survival and relative survival at 3, 5 and 10 years. RESULTS: Our crude incidence rate was 9.13 cases/100,000 inhabitants for invasive and 2.59 for "in situ" melanomas. A statistically significant increase in incidence was found for melanomas of less than 1 mm in Breslow index and in males. 10-year observed and relative survival rates were 64.1 and 83.1%, respectively. CONCLUSIONS: We found an increasing trend in the incidence of low-risk melanoma and a survival rate similar to that reported elsewhere in Europe.
Authors: Susana Puig; Joaquim Marcoval; Cristina Paradelo; Antoni Azon; Ramon Bartralot; Susana Bel; Xavier Bigata; Aram Boada; Antoni Campoy; Cristina Carrera; Neus Curco; Joan Dalmau; Carlos Ferrándiz; Josep R Ferreres; Manel Formigon; Fernando Gallardo; Alberto Gonzalez; Miquel Just; Enric Llistosella; Rosa M Marti; M Elena Nogues; Ramon Pedragosa; Josep A Pujol; Rodrigo Roldán-Marín; Mireia Sabat; Montserrat Salleras; Juan A Smandia; Pedro Zaballos; Estel Plana; Josep Malvehy Journal: Acta Derm Venereol Date: 2015-04 Impact factor: 4.437
Authors: L M Hollestein; S A W van den Akker; T Nijsten; H E Karim-Kos; J W Coebergh; E de Vries Journal: Ann Oncol Date: 2011-05-04 Impact factor: 32.976
Authors: L Sacchetto; R Zanetti; H Comber; C Bouchardy; D H Brewster; P Broganelli; M D Chirlaque; D Coza; J Galceran; A Gavin; M Hackl; A Katalinic; S Larønningen; M W J Louwman; E Morgan; T E Robsahm; M J Sanchez; L Tryggvadóttir; R Tumino; E Van Eycken; S Vernon; V Zadnik; S Rosso Journal: Eur J Cancer Date: 2018-01-31 Impact factor: 9.162
Authors: M Arnold; C Holterhues; L M Hollestein; J W W Coebergh; T Nijsten; E Pukkala; B Holleczek; L Tryggvadóttir; H Comber; M J Bento; Ch S Diba; R Micallef; M Primic-Žakelj; M I Izarzugaza; J Perucha; R Marcos-Gragera; J Galceran; E Ardanaz; R Schaffar; A Pring; E de Vries Journal: J Eur Acad Dermatol Venereol Date: 2013-08-21 Impact factor: 6.166
Authors: Veronica Di Carlo; Charles A Stiller; Nora Eisemann; Andrea Bordoni; Melissa Matz; Maria P Curado; Laetitia Daubisse-Marliac; Mikhail Valkov; Jean-Luc Bulliard; David Morrison; Chris Johnson; Fabio Girardi; Rafael Marcos-Gragera; Mario Šekerija; Siri Larønningen; Eunice Sirri; Michel P Coleman; Claudia Allemani Journal: Br J Dermatol Date: 2022-07-28 Impact factor: 11.113